Do GLP-1 medications cause muscle loss?
Yes — some lean-mass loss occurs on GLP-1 medications, but the key context is that this happens with virtually all substantial weight loss, including dieting and bariatric surgery. When you lose weight, you lose a mix of fat and fat-free (lean) tissue. The often-cited "quarter rule" holds that about one-quarter of weight lost is fat-free mass, though a 2024 review in Circulation notes this is an approximation rather than a fixed law.
Because GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce large total weight loss, the absolute number of kilograms of lean mass lost can look sizeable. But fat loss is proportionally larger, so the ratio of lean mass to total body weight typically improves. In the STEP 1 semaglutide trial, total lean body mass fell about 9.7%, yet the proportion of lean mass relative to total body weight rose by about 3 percentage points (STEP 1 DXA substudy; NEJM, 2021).
An important nuance: "lean mass" measured on a DXA scan is not the same thing as skeletal muscle. Fat-free mass also includes organs, bone, connective tissue, and body water, and up to about 15% of fat tissue itself is fat-free. So DXA lean-mass loss tends to overstate the true loss of functional muscle (Neeland et al., Diabetes, Obesity and Metabolism, 2024).
How much of the weight lost is muscle? What the trials show
Estimates vary by drug, dose, population, and how muscle was measured. A 2024 network meta-analysis of 22 randomized trials found GLP-1 receptor agonists reduced lean mass by roughly 25% of total weight lost, with no significant change in the percentage of lean mass relative to body weight (Systematic review and network meta-analysis, 2024).
Individual flagship trials span a wider range. Analyses of STEP 1 (semaglutide) put lean mass at roughly 40-45% of total weight lost, while SURMOUNT-1 (tirzepatide) came in lower, around 26% (Neeland et al., DOM, 2024; Circulation, 2024). Liraglutide combined with exercise essentially preserved or slightly increased lean mass. The table below summarizes the published figures.
Researchers increasingly describe this muscle loss as largely "adaptive" — proportional to the weight lost and accompanied by improved muscle quality and insulin sensitivity. GLP-1 receptors are not found on human skeletal muscle, so any muscle effects are indirect, working through weight loss, reduced inflammation, and better insulin action (Circulation, 2024). Still, absolute lean-mass loss is real, which is why nutrition and exercise countermeasures matter.
Why preserving muscle matters
Muscle does more than move you. Skeletal muscle is the body's main site for insulin-stimulated glucose uptake, so preserving it supports metabolic health. It also drives strength, balance, mobility, and independence — losing too much raises the risk of falls, fractures, and functional decline, the cluster of problems clinicians call sarcopenia (Circulation, 2024).
Muscle also props up your resting metabolism, though the effect is often overstated. Each kilogram of muscle burns roughly 13 kcal/day at rest, versus about 4 kcal/day for a kilogram of fat (Circulation, 2024). Protecting lean tissue helps blunt the drop in energy expenditure that accompanies weight loss and can make maintenance easier.
Risk is not equal for everyone. Older adults, people who are already frail or sedentary, and those with type 2 diabetes or other chronic disease start with less muscle reserve and lose it faster, so muscle preservation is especially important for them (Springer scoping review on GLP-1s and sarcopenia, 2026). For younger, more muscular people, the same absolute loss may matter less. These are general educational points — your individual risk should be assessed by a licensed clinician.
Evidence-based way #1: Get enough protein
Adequate protein is the most consistently supported nutritional strategy for protecting lean mass during weight loss. In a calorie deficit, higher protein intake helps offset the muscle-protein breakdown that drives lean-mass loss, and the effect is strongest when paired with resistance training.
Published targets vary by age, activity, and how the goal is framed. The ranges below reflect peer-reviewed guidance, not personalized advice — a clinician or registered dietitian should tailor an amount to you, especially if you have kidney disease or other conditions where protein needs adjustment. GLP-1 medications suppress appetite, which can make hitting a protein target harder, so spreading protein across meals is a common practical tactic.
- General adults maintaining muscle with exercise: about 1.4-2.0 g/kg body weight/day (International Society of Sports Nutrition Position Stand, 2017).
- Overweight/obese adults losing weight: a minimum around 1.3 g/kg/day is associated with better muscle retention; below ~1.0 g/kg/day raises the risk of muscle decline (Clinical Nutrition ESPEN meta-analysis, 2024).
- Older adults on GLP-1 therapy: roughly 1.2-1.6 g/kg/day, alongside resistance exercise (Current Nutrition Reports scoping review, 2026).
- Trained people in a marked calorie deficit wanting maximal muscle retention: about 2.3-3.1 g/kg of fat-free mass/day (ISSN Position Stand, 2017). In one controlled study, athletes eating ~2.3 g/kg lost only 0.3 kg of lean mass vs 1.6 kg at ~1.0 g/kg (Mettler et al., 2010).
- Distribute protein across meals (roughly 20-40 g per meal, with high-quality sources) rather than loading it into one sitting (ISSN Position Stand, 2017).
Evidence-based way #2: Resistance training
Resistance (strength) training is the single most effective exercise strategy for preserving muscle during weight loss, and unlike endurance exercise alone it also improves strength (Circulation, 2024). Combining resistance training with adequate protein produces the best lean-mass retention, and in some controlled deficits people have even gained lean mass while losing fat (Longland et al., AJCN, 2016).
Systematic reviews in people with overweight or obesity confirm that adding resistance exercise to a weight-loss program preserves fat-free mass and improves muscle function (Binmahfoz et al., BMJ Open Sport & Exercise Medicine, 2025). Both machines and free weights work; the essential ingredient is progressively challenging the muscles, typically two or more sessions per week.
One practical caveat specific to GLP-1 users: fatigue and reduced food intake early in treatment can make training harder, and low protein plus low activity is the combination most likely to accelerate lean-mass loss (Circulation, 2024). Building movement in gradually, and coordinating an exercise plan with a clinician, addresses this directly. Nothing here should be taken as a prescription to start or intensify exercise on your own — get individualized clearance first.
Evidence-based way #3: Lose weight gradually
The faster you lose weight, the more lean mass tends to go with it. Research in athletes and dieters consistently shows that steeper calorie deficits and quicker weight loss produce greater fat-free-mass loss, while a more moderate pace protects muscle (Protein recommendations review, IJSNEM, 2018).
This is one reason clinicians titrate GLP-1 doses slowly and pair them with lifestyle support rather than pushing for the fastest possible drop. A steadier trajectory also tends to be more sustainable, which matters because a large share of lost weight — and the metabolic adaptations behind it — can return over the years that follow (Circulation, 2024).
Practically, gradual loss, adequate protein, and resistance training reinforce each other: the slower pace reduces the muscle-breakdown pressure, protein supplies the building blocks, and training signals the body to keep the muscle it has.
Emerging research: muscle-sparing drug combinations
A major frontier in obesity medicine is improving the quality of weight loss — maximizing fat loss while sparing muscle. The most advanced example is bimagrumab, an antibody that blocks activin type II receptors (part of the myostatin pathway) to build muscle. In the phase 2b BELIEVE trial presented at ADA 2025 and published in Nature Medicine (2026), bimagrumab plus semaglutide drove about 22% total weight loss, and 92.8% of that loss came from fat, versus 71.8% with semaglutide alone; lean mass fell only about 2.6% in the combination group, and bimagrumab alone increased lean mass by about 2.5% (ADA Meeting News, 2025).
Other investigational approaches include amylin-analog combinations (such as cagrilintide paired with semaglutide) and triple agonists like retatrutide, which are being studied partly for their body-composition effects. These agents are still in trials and are not FDA-approved as muscle-preserving therapies, so their real-world muscle benefits remain to be confirmed. We include them here as research context, not as treatment recommendations.
The broader takeaway from this research is reassuring: muscle loss on GLP-1s is not inevitable or fixed, and the field is actively engineering ways to reduce it. For now, the tools already in your hands — protein, resistance training, and a sensible pace — are the evidence-based levers, applied in partnership with your clinician.
A note on supplements and "muscle-preserving" products
Supplements marketed as "natural Ozempic," muscle-protecting powders, or fat-burner-plus-muscle blends are not FDA-approved to treat obesity or to prevent muscle loss, and they are not equivalent to prescription GLP-1 medications. The FDA does not evaluate the efficacy of dietary supplements before they are sold, so effectiveness claims are largely unverified.
The evidence-based nutrition lever is dietary protein from food and, where convenient, protein supplements like whey — which the ISSN describes as a practical way to hit protein targets while limiting calories (ISSN Position Stand, 2017). Compounds sometimes promoted for muscle, such as BCAAs or HMB, have weaker evidence for meaningful muscle preservation during weight loss than whole-food protein plus resistance training. Talk to a licensed clinician or registered dietitian before adding any supplement, especially alongside a GLP-1 medication.